Exercise capacity deterioration in patients with COPD: Longitudinal evaluation over 5 years

Chest

Volumn 128, Issue 1, 2005, Pages 62-69

  Oga, Toru ^a   Nishimura, Koichi ^b   Tsukino, Mitsuhiro ^c   Sato, Susumu ^a   Hajiro, Takashi ^d   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO KATSURA HOSPITAL   (Japan)

^c Hikone Municipal Hospital   (Japan)

^d SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Airflow limitation; COPD; Dynamic ventilatory constraint; Exercise capacity; Longitudinal study; Progressive cycle ergometry

Indexed keywords

ADULT; AGED; ARTICLE; BICYCLE ERGOMETRY; BREATHING RATE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE SEVERITY; EXERCISE; FORCED EXPIRATORY VOLUME; HUMAN; LONGITUDINAL STUDY; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG MINUTE VOLUME; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; OUTPATIENT; OXYGEN CONSUMPTION; PHYSICAL CAPACITY; PRIORITY JOURNAL; TIDAL VOLUME;

EID: 22244453078     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.1.62     Document Type: Article

References (36)

1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ ERS position paper. Eur Respir J 2004; 23:932-946
2. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1:1645-1648
3. Burrows B, Bloom JW, Traver GA, et al. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 1987; 317:1309-1314
4. Gross NJ. Extrapulmonary effects of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2001; 7:84-92
5. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001; 56:880-887
6. Oga T, Nishimura K, Tsukino M, et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167:544-549
7. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005-1012
8. Pinto-Plata VM, Cote C, Cabral H, et al. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004; 23:28-33
9. Strachan D, Sherrill D. Statistical methods. Eur Respir J 1998; 12:S23-S27
10. Calverley PM, Spencer S, Willits L, et al. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest 2003; 124:1350-1356
11. Medical Section of the American Lung Association. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1994; 152:1107-1136
12. Japan Society of Chest Diseases. The predicted values of pulmonary function testing in Japanese [in Japanese]. Jpn J Thoracic Dis 1993; 31:Appendix
13. Oga T, Nishimura K, Tsukino M, et al. The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease: a comparison of three different exercise tests. Am J Respir Crit Care Med 2000; 161:1897-1901
14. Oga T, Nishimura K, Tsukino M, et al. A comparison of the effects of salbutamol and ipratropium bromide on exercise endurance in patients with COPD. Chest 2003; 123:1810-1816
15. Borg GAV. Psychophysical basis of perceived exertion. Med Sci Sports Exerc 1982; 14:377-381
16. Littell RC, Milliken GA, Stroup WW, et al. SAS System for Mixed Models. Cary, NC: SAS Institute, 1996
17. Oga T, Nishimura K, Tsukino M, et al. Relationship between different indices of exercise capacity and clinical measures in patients with chronic obstructive pulmonary disease. Heart Lung 2002; 31:374-381
18. Jones NL, Makrides L, Hitchcock C, et al. Normal standards for an incremental progressive cycle ergometer test. Am Rev Respir Dis 1985; 131:700-708
19. American Thoracic Society; American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167:211-277
20. O'Donnell DE. Ventilatory limitations in chronic obstructive pulmonary disease. Med Sci Sports Exerc 2001; 33:S647-S655
21. O'Donnell DE, Bertley JC, Chau LK, et al. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med 1997; 155:109-115
22. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:770-777
23. Marin JM, Carrizo SJ, Gascon M, et al. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:1395-1399
24. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153:967-975
25. O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation: the role of lung hyperinflation. Am Rev Respir Dis 1993; 148:1351-1357
26. Cahalin L, Pappagianopoulos P, Prevost S, et al. The relationship of the 6-min walk test to maximal oxygen consumption in transplant candidates with end-stage lung disease. Chest 1995; 108:452-459
27. Turner SE, Eastwood PR, Cecins NM, et al. Physiologic responses to incremental and self-paced exercise in COPD: a comparison of three tests. Chest 2004; 126:766-773
28. Guyatt GH, Thompson PJ, Berman LB, et al. How should we measure function in patients with chronic heart and lung disease? J Chron Dis 1985; 38:517-524
29. Wijkstra PJ, TenVergert EM, Van der Mark TW, et al. Relation of lung function, maximal inspiratory pressure, dyspnoea, and quality of life with exercise capacity in patients with chronic obstructive pulmonary disease. Thorax 1994; 49:468-472
30. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-1303
31. Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004; 59:387-395
32. Carpenter J, Pocock S, Lamm CJ. Coping with missing data in clinical trials: a model-based approach applied to asthma trials. Stat Med 2002; 21:1043-1166
33. Park T. A comparison of the generalized estimating equation approach with the maximum likelihood approach for repeated measurements. Stat Med 1993; 12:1723-1732
34. Oga T, Nishimura K, Tsukino M, et al. Longitudinal changes in airflow limitation and airway hyperresponsiveness in patients with stable asthma. Ann Allergy Asthma Immunol 2002; 89:619-625
35. Oga T, Nishimura K, Tsukino M, et al. Longitudinal changes in health status using the Chronic Respiratory Disease Questionnaire and pulmonary function in patients with stable chronic obstructive pulmonary disease. Qual Life Res 2004; 13:1109-1116
36. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1418-1422